Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000543997 | SCV000628777 | likely benign | Neurofibromatosis, type 1 | 2024-07-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000565472 | SCV000670422 | uncertain significance | Hereditary cancer-predisposing syndrome | 2016-02-28 | criteria provided, single submitter | clinical testing | The p.M2468V variant (also known as c.7402A>G), located in coding exon 50 of the NF1 gene, results from an A to G substitution at nucleotide position 7402. The methionine at codon 2468 is replaced by valine, an amino acid with highly similar properties. This variant was previously reported in the SNPDatabase as rs151211377. Based on data from the NHLBI Exome Sequencing Project (ESP), the G allele has an overall frequency of approximately 0.02% (2/13006) total alleles studied, having been observed in 0.05% (2/4406) African American alleles. To date, this alteration has been detected with an allele frequency of approximately 0.001% (greater than 110000alleles tested) in our clinical cohort.This amino acid position is highly conserved in available vertebrate species. However, this alteration is predicted to be benign and tolerated by PolyPhen and SIFT in silico analyses, respectively.Since supporting evidence is limited at this time, the clinical significance of this alterationremains unclear. |
Gene |
RCV001562519 | SCV001785295 | uncertain significance | not provided | 2021-06-21 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV000543997 | SCV002561070 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004559163 | SCV005048770 | likely benign | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2023-08-03 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Fulgent Genetics, |
RCV005010492 | SCV005639963 | uncertain significance | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2024-05-14 | criteria provided, single submitter | clinical testing |